Form 4: ResMed Counsel Sells Shares Under 10b5-1 Plan

ResMed's Global General Counsel, Michael J. Rider, sold 50 shares of common stock for $241.75 per share under a pre-arranged 10b5-1 plan.

Summary

• Michael J. Rider, Global General Counsel of ResMed Inc., reported a sale of company common stock.
• The transaction involved 50 shares of ResMed Common Stock.
• The shares were sold at a price of $241.75 per share.
• The sale was executed on January 2, 2026.
• Following this transaction, Michael J. Rider beneficially owns 9,741 shares directly.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned sale of a small number of shares by an insider under a Rule 10b5-1 plan, which is generally considered neutral as it does not signal new information about the company's prospects.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• An insider, Michael J. Rider, sold 50 shares of company common stock.

Future Outlook

NA

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Minor impact as a small, pre-planned insider sale typically does not signal significant changes in company prospects.

Key Dates

Recommendation

The filing details a small, pre-planned sale of shares by an officer under a Rule 10b5-1 plan. This type of transaction is generally considered routine and does not provide new material information that would warrant a change in investment recommendation. The fundamental outlook for ResMed Inc. remains unchanged based solely on this filing.

Keywords

ResMed, RMD, insider trading, Form 4, stock sale, Michael J. Rider, 10b5-1 plan, corporate governance